DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics

DCAD - 利用新型 AI 增强型超快速蛋白质组学开发更好的冠状动脉疾病诊断方法

• 批准号: 10072712
• 金额: $ 86.54万
• 依托单位: ELIPTICA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072712
• 关键词: DCAD; Developing; better; diagnostics; Coronary

**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease**Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic experiments.The project objective, with support from project partners Bruker UK Limited and UK Biobank, is to demonstrate that our platform can develop new insights into CVD through the application of AI to a large reference baseline of the human proteome and thus identify novel multi protein panel biomarkers (MPPB's) more quickly and accurately than is currently the case.Our MPPB's will be readily translatable into blood tests that more accurately identify patients at high risk of CVD (e.g. imminent risk of heart attack) or potentially identify the subset of patients most likely to benefit from a particular therapy. Eliptica was founded to enable Precision Medicine (i.e. to ensure the right patients receive the right treatments and medical interventions at the right time).

**开发新型蛋白质组学技术以改善冠心病的早期诊断**Eliptica Limited 提出了一项为期 24 个月的工作计划，该计划基于人工智能增强、超快、低成本的基于质谱 (MS) 的蛋白质组学新技术，由弗朗西斯·克里克研究所 (Francis Crick Institute) 的创始人开发，仅需要极少量的血浆即可进行高质量、群体规模的蛋白质组实验。项目目标，在项目合作伙伴布鲁克 (Bruker) 的支持下UK Limited 和 UK Biobank 旨在证明我们的平台可以通过将人工智能应用于人类蛋白质组的大型参考基线来开发对 CVD 的新见解，从而比目前更快、更准确地识别新型多蛋白组生物标志物 (MPPB)我们的 MPPB 将很容易转化为血液测试，从而更准确地识别 CVD 高风险患者（例如即将发生心脏病的风险），或者潜在地识别最有可能从特定治疗中受益的患者子集。 Eliptica 的成立是为了实现精准医疗（即确保正确的患者在正确的时间接受正确的治疗和医疗干预）。